0.00Open8.72Pre Close0 Volume0 Open Interest59.00Strike Price0.00Turnover0.00%IV-2.17%PremiumDec 6, 2024Expiry Date9.79Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.64Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet